Evidence-based position statement on the management of irritable bowel syndrome in North America.
D000929:Antidepressive Agents, Tricyclic / Q000627:therapeutic use; D000930:Antidiarrheals / Q000627:therapeutic use; D001521:Behavior Therapy; D002243:Carbolines / Q000627:therapeutic use; D002400:Cathartics / Q000627:therapeutic use; D003109:Colonic Diseases, Functional / Q000175:diagnosis / Q000453:epidemiology / Q000503:physiopathology / Q000628:therapy; D003937:Diagnosis, Differential; D019317:Evidence-Based Medicine; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D008139:Loperamide / Q000627:therapeutic use; D009656:North America / Q000453:epidemiology; D010276:Parasympatholytics / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D012702:Serotonin Antagonists / Q000627:therapeutic use; D017366:Serotonin Receptor Agonists / Q000627:therapeutic use; D012720:Severity of Illness Index
D000929:Antidepressive Agents, Tricyclic; D000930:Antidiarrheals; D002243:Carbolines; D002400:Cathartics; D007211:Indoles; D010276:Parasympatholytics; D012702:Serotonin Antagonists; D017366:Serotonin Receptor Agonists; C090840:alosetron; C105050:tegaserod; D008139:Loperamide